Coversyl: Effective Blood Pressure Control for Cardiovascular Health
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.60 | $48.09 (0%) | 🛒 Add to cart |
| 60 | $1.40 | $96.17 $84.15 (12%) | 🛒 Add to cart |
| 90 | $1.20 | $144.26 $108.19 (25%) | 🛒 Add to cart |
| 120 | $1.15 | $192.35 $138.25 (28%) | 🛒 Add to cart |
| 180 | $1.10 | $288.52 $198.36 (31%) | 🛒 Add to cart |
| 270 | $0.90 | $432.78 $243.44 (44%) | 🛒 Add to cart |
| 360 | $0.80
Best per pill | $577.04 $288.52 (50%) | 🛒 Add to cart |
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.00 | $40.07 (0%) | 🛒 Add to cart |
| 30 | $1.70 | $60.11 $51.09 (15%) | 🛒 Add to cart |
| 60 | $1.50 | $120.22 $90.16 (25%) | 🛒 Add to cart |
| 90 | $1.34 | $180.32 $120.22 (33%) | 🛒 Add to cart |
| 120 | $1.20 | $240.43 $144.26 (40%) | 🛒 Add to cart |
| 180 | $1.15 | $360.65 $207.37 (43%) | 🛒 Add to cart |
| 270 | $1.10 | $540.97 $297.54 (45%) | 🛒 Add to cart |
| 360 | $1.00
Best per pill | $721.30 $360.65 (50%) | 🛒 Add to cart |
| Product dosage: 8mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $3.01 | $60.11 (0%) | 🛒 Add to cart |
| 30 | $2.81 | $90.16 $84.15 (7%) | 🛒 Add to cart |
| 60 | $2.60 | $180.32 $156.28 (13%) | 🛒 Add to cart |
| 90 | $2.40 | $270.49 $216.39 (20%) | 🛒 Add to cart |
| 120 | $2.20 | $360.65 $264.48 (27%) | 🛒 Add to cart |
| 180 | $2.00 | $540.97 $360.65 (33%) | 🛒 Add to cart |
| 270 | $1.70 | $811.46 $459.83 (43%) | 🛒 Add to cart |
| 360 | $1.50
Best per pill | $1081.95 $540.97 (50%) | 🛒 Add to cart |
Coversyl (perindopril) is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of essential hypertension and stable coronary artery disease. As a prodrug, it is hydrolyzed to perindoprilat, its active metabolite, which exerts its therapeutic effect by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This mechanism results in decreased vasoconstriction, reduced aldosterone secretion, and ultimately, a lowering of systemic vascular resistance and blood pressure. Its clinical profile is supported by extensive evidence from large-scale outcome studies, establishing its role in long-term cardiovascular risk reduction.
Features
- Active ingredient: Perindopril (as perindopril arginine or perindopril erbumine)
- Pharmacological class: Angiotensin-converting enzyme (ACE) inhibitor
- Available formulations: Oral tablets (2 mg, 4 mg, 8 mg strengths)
- Administration: Once-daily dosing
- Prodrug: Requires enzymatic conversion to active metabolite perindoprilat
- Long duration of action: Provides 24-hour hemodynamic control
Benefits
- Achieves significant and sustained reduction in both systolic and diastolic blood pressure.
- Reduces the long-term risk of major cardiovascular events, including myocardial infarction and stroke.
- Demonstrates organoprotective effects, particularly on vascular endothelium and cardiac remodeling.
- Improves endothelial function and increases arterial compliance.
- May be used as monotherapy or in combination with other antihypertensive agents like indapamide or amlodipine.
- Generally well-tolerated with a favorable side effect profile in most patient populations.
Common use
Coversyl is primarily prescribed for the management of essential hypertension in adult patients. It is also indicated in the treatment of stable coronary artery disease to reduce the risk of cardiovascular events in patients with a history of myocardial infarction or revascularization procedures. The medication may be used as first-line therapy or as an adjunct to other antihypertensive regimens. Its use extends to certain patient populations with heart failure, though this is typically off-label and requires careful clinical assessment.
Dosage and direction
The recommended initial dose for hypertension is 4 mg once daily, which may be increased to 8 mg after one month if adequate blood pressure control is not achieved. For elderly patients or those with renal impairment, a starting dose of 2 mg daily is recommended. Tablets should be taken orally, preferably at the same time each day, with or without food. Dosage adjustments should be based on therapeutic response and tolerability, with regular monitoring of blood pressure, renal function, and serum electrolytes. The maximum recommended daily dose is 8 mg.
Precautions
Patients should be monitored for the development of angioedema, particularly during the first month of treatment. Renal function should be assessed before initiation and periodically during therapy, especially in patients with pre-existing renal impairment, heart failure, or volume depletion. Serum potassium levels require monitoring, particularly when used concomitantly with potassium-sparing diuretics or potassium supplements. Caution is advised in patients with aortic stenosis or hypertrophic cardiomyopathy. Use during pregnancy is contraindicated due to potential fetal harm.
Contraindications
Coversyl is contraindicated in patients with a history of angioedema related to previous ACE inhibitor therapy. It is contraindicated in patients with hereditary or idiopathic angioedema. The medication must not be used during pregnancy, particularly in the second and third trimesters. Concomitant use with aliskiren-containing products is contraindicated in patients with diabetes mellitus. It is contraindicated in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney.
Possible side effects
Common adverse reactions (≥1%) include: cough, dizziness, headache, asthenia, and gastrointestinal disturbances. Less frequent side effects may include: hypotension, hyperkalemia, renal impairment, angioedema, rash, and taste disturbance. Rare but serious adverse effects include neutropenia/agranulocytosis, hepatic enzyme elevations, and pancreatitis. The incidence of cough is higher in women and non-smokers, typically presenting as a persistent dry cough that may necessitate discontinuation of therapy.
Drug interaction
Concomitant use with diuretics may potentiate hypotensive effects. NSAIDs may reduce the antihypertensive efficacy and increase the risk of renal impairment. Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase the risk of hyperkalemia. Concurrent use with lithium may increase lithium serum concentrations and toxicity risk. Dual blockade of the renin-angiotensin system with ARBs or aliskiren increases the risk of renal impairment, hyperkalemia, and hypotension.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is near the time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed dose. Consistent daily administration is important for maintaining stable blood pressure control.
Overdose
Symptoms of overdose may include marked hypotension, bradycardia, circulatory shock, renal failure, hyperkalemia, and electrolyte imbalances. Management should include supportive measures with volume expansion with normal saline to correct hypotension. Hemodialysis may be effective in removing perindoprilat. Bradycardia may require atropine administration. Serum electrolytes and renal function should be monitored closely, with appropriate correction of abnormalities.
Storage
Store at room temperature (15-30°C or 59-86°F) in the original container, protected from light and moisture. Keep tightly closed and out of reach of children. Do not use after the expiration date printed on the packaging. Tablets should not be removed from their blister packaging until immediately before administration.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made by qualified healthcare professionals based on individual patient characteristics. The prescribing physician should be consulted for complete information regarding indications, dosage, warnings, and precautions. Patients should not alter their treatment regimen without medical supervision.
Reviews
Clinical trials and post-marketing surveillance data demonstrate that Coversyl provides effective blood pressure control in approximately 70-80% of patients with mild to moderate hypertension. The ASCOT-BPLA and EUROPA trials established its efficacy in reducing cardiovascular morbidity and mortality. Patient satisfaction surveys indicate good tolerability, though the characteristic ACE inhibitor cough remains a common reason for discontinuation in susceptible individuals. Long-term follow-up studies confirm maintained efficacy and safety profiles over extended treatment periods.